ClinicalTrials.gg
Sign In

Lymphoma, Large-Cell, Immunoblastic clinical trials

The registry lists 491 studies for Lymphoma, Large-Cell, Immunoblastic across more than 10 countries. 2 are recruiting or about to start. 1 of them are mainly about Lymphoma, Large-Cell, Immunoblastic (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.

Get an email when these change. Save the Lymphoma, Large-Cell, Immunoblastic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
367
Terminated
65
Status unknown
31
Withdrawn
21
Active, not recruiting
4
Recruiting
2

Phase

Phase 1
201
Phase 2
197
Phase 3
50
Early Phase 1
3
Phase 4
1

Where

United States
432
Italy
19
Canada
17
Germany
16
Switzerland
11
France
11

Who runs them

National Cancer Institute (NCI) (59) · Fred Hutchinson Cancer Center (48) · Case Comprehensive Cancer Center (23) · Memorial Sloan Kettering Cancer Center (21) · City of Hope Medical Center (19) · Northwestern University (15) · Masonic Cancer Center, University of Minnesota (14) · Roswell Park Cancer Institute (13)

What is being tested here

Drugs under test in Lymphoma, Large-Cell, Immunoblastic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Cyclophosphamide0450
Rituximab0143
Fludarabine phosphate0135
Fludarabine0135
Etoposide0432
Busulfan0124
Melphalan0222
Mycophenolic Acid0122
Filgrastim0220
Cyclosporine0218

Drug classes tested here Alkylating agents 85 · Antimetabolites 78 · Calcineurin inhibitors 32 · Corticosteroids 25 · Antimitotic agents 23

Who these studies take

Of the 2 Lymphoma, Large-Cell, Immunoblastic studies recruiting now, 1 (50%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 2
AgeWomenMen
100 (0%)0 (0%)
181 (50%)1 (50%)
301 (50%)1 (50%)
401 (50%)1 (50%)
501 (50%)1 (50%)
652 (100%)2 (100%)
752 (100%)2 (100%)
852 (100%)2 (100%)

Across all 491 studies, recruiting or not: 31% stop at 75 or younger and 19% at 65; 36% take children; 0% are for women only and <1% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, Large-Cell, Immunoblastic studies take

Of 27 phase 2 interventional studies under Lymphoma, Large-Cell, Immunoblastic, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 151 mo23–64 · 13 studies——
Phase 264 mo30–108 · 27 studies—64 mo30–108 · 27 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 491. Browse all 491 → or search them.